Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Cue Biopharma (CUE) Stock Price & Analysis

671 Followers

CUE Stock Chart & Stats

$18.66-$0.10(-0.53%)
At close: 4:00 PM EST
$20$30Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$18.51 - $19.99
52-Week Range
$4.95 - $45.50
Previous Close
$18.76
Volume
N/A
Average Volume (3M)
163.66K
Market Cap
$136.28M
Enterprise Value
$191.53M
Total Cash (Recent Filing)
$17.39M
Total Debt (Recent Filing)
$8.81M
Price to Earnings (P/E)
―
Beta
3.26
Next Earnings
Nov 12, 2026 (Est.)
EPS Estimate
-2.24
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

CUE-221 Clinical Differentiation

Positive Phase 2 results strengthen the lead program’s development case by showing statistically significant, dose-responsive efficacy and benefit lasting after treatment ended. The favorable safety profile and planned registration-enabling study could improve the company’s opportunity to establish a differentiated allergy biologic.

Improving Revenue Trajectory

Meaningful multi-year revenue expansion indicates that Cue Biopharma is building greater commercial or collaboration-related activity despite remaining clinical-stage. Continued top-line scaling can improve operating leverage over time and provide a stronger base for funding research, development, and future product advancement.

Experienced Financial Leadership

Appointing an experienced life sciences CFO may strengthen capital-markets execution, financial controls, and preparation for the company’s next development stage. That expertise is relevant to managing financing needs and supporting disciplined execution as CUE-221 advances toward later-stage clinical development.

Bears Say

Heavy Cash Consumption

Sustained cash burn means Cue Biopharma is consuming substantial resources to maintain operations and advance its pipeline. Ongoing negative operating and free cash flow increases dependence on future financing or partnership proceeds, potentially limiting strategic flexibility and creating funding pressure over the next several quarters.

Deepening Operating Losses

Large and worsening operating and net losses show that current activity is not yet translating into sustainable profitability. Even with improving revenue and near break-even gross profit, insufficient cost absorption could prolong reliance on external capital and delay the point at which the business funds growth internally.

Equity Erosion And Financing Risk

Rapid equity erosion and shrinking assets weaken the balance sheet’s ability to support continued development. Although nominal debt remains modest, the reduced capital base and higher debt-to-equity relationship increase financing and dilution risk, making future capital allocation less flexible during clinical execution.

Cue Biopharma News

CUE FAQ

What was Cue Biopharma’s price range in the past 12 months?
Cue Biopharma lowest stock price was $4.95 and its highest was $45.50 in the past 12 months.
What is Cue Biopharma’s market cap?
Cue Biopharma’s market cap is $136.28M.
When is Cue Biopharma’s upcoming earnings report date?
Cue Biopharma’s next earnings report is estimated for Nov 12, 2026 (not yet confirmed), which is today.
How were Cue Biopharma’s earnings last quarter?
Cue Biopharma released its earnings results on Aug 17, 2026. The company reported -$24.14 earnings per share for the quarter, missing the consensus estimate of -$1.69 by -$22.45.
Is Cue Biopharma overvalued?
According to Wall Street analysts Cue Biopharma’s price is currently Undervalued.
Does Cue Biopharma pay dividends?
Cue Biopharma does not currently pay dividends.
What is Cue Biopharma’s EPS estimate?
Cue Biopharma’s EPS estimate is -2.24.
How many shares outstanding does Cue Biopharma have?
Cue Biopharma has 7,264,414 shares outstanding.
What happened to Cue Biopharma’s price movement after its last earnings report?
Cue Biopharma reported an EPS of -$24.14 in its last earnings report, missing expectations of -$1.69. Following the earnings report the stock price went down -7.019%.
Which hedge fund is a major shareholder of Cue Biopharma?
Hedge funds hold Cue Biopharma shares: the largest hedge-fund position in Cue Biopharma is 70,128,813 shares, and hedge funds increased their holdings by 335.0K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology